B+
Bull case
20%
Probability
Target price
$46.76
Analysis reference price unavailable
Analysis 2025-10-29 · RankAlpha Sentiment AI
VCYT
VeracyteCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Sustained adoption of Veracyte’s core genomic tests combined with favorable reimbursement headlines and one or more commercial partnerships could drive above-consensus revenue growth and margin expansion, supporting multiple expansion to reach the bull target within 12 months.
Posture
Mixed
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-10-26.
What can break
Clinical data or regulatory setbacks
Momentum
83
Value
61
Sentiment
34
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $39.57 · Bull $46.76 · Bear $28.78Analysis 2025-10-29; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-29 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $57.82
Why
Momentum83 · Δ7d +6.1
Value61 · Δ7d -0.5
Sentiment34 · Δ7d -11.0
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-10-26.
- • Value remains the lead driver in the composite, 7D delta -0.5.
Contradictions & invalidation
- • Clinical data or regulatory setbacks
- • Competition from alternative diagnostics or larger lab networks
- • Slower-than-expected test adoption, adverse reimbursement decisions, or increased competitive pricing pressure could compress revenues and margins, driving the share toward the bear target over the next 12 months.
Catalyst clock
No dated catalyst is available.
Quarterly earnings release
Lead driver: Value · See fundamentals
Momentum
83
8% active weight
Current posture
7d trendFlat
Δ7d
+6.1
Δ21d
+42.8
Value
61
47% active weight
Current posture
7d trendFlat
Δ7d
-0.5
Δ21d
-0.7
Sentiment
34
45% active weight
Current posture
7d trendSoftening
Δ7d
-11.0
Δ21d
-10.5
Why this grade
Composite grade C. Momentum 82.6 / Value 60.8 / Sentiment 34.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2025-10-29. Scenario method
Most likely
B
Base case
60%
Probability
Target price
$39.57
Analysis reference price unavailable
Analysis 2025-10-29 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$28.78
Analysis reference price unavailable
Analysis 2025-10-29 · RankAlpha Sentiment AI
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$3.87B
Beta
1.91
Shares Out
80.39M
P/E (TTM)
115.1
P/S (TTM)
6.97
P/FCF (TTM)
35.12
Rev YoY
+15.5%
EPS YoY
-2584.8%
Gross Margin
+71.1%
Op Margin
+17.2%
Net Debt
-$373.24M
Current Ratio
9.16
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data